FisMat2017 - Submission - View

Abstract's title: Resorbable glass capillaries for combined light delivery
Submitting author: Davide Janner
Affiliation: Politecnico di Torino - DISAT
Affiliation Address: Corso Duca degli Abruzzi 24 10129 Torino Italy
Country: Italy
Oral presentation/Poster (Author's request): Oral presentation
Other authors and affiliations: Edoardo Ceci-Ginistrelli (Politecnico di Torino), Diego Pugliese (Politecnico di Torino), Nadia G. Boetti (Istituto Superiore Mario Boella), Daniel Milanese (Politecnico di Torino)
Abstract

Among biophotonic techniques, Photodynamic Therapy (PDT) has demonstrated great potentialities towards the development of minimally invasive cancer and infection treatment. Despite PDT has been approved for clinical practice and it is currently used for the treatment of some diseases, its application is not yet widespread [1]. Besides in conventional PDT the photosensitizer is administrated through systemic way and the light irradiation is external to the body. This limits the application to superficial skin cancer and has some drawbacks in terms of procedure and discomfort for the patient.

Optical fibers have been already used and allow for deep tissue light delivery, but still associated to systemic sensitizer. Standard fibers are made of silica, thus biocompatible but dangerous in case of damage during treatment.

We report on the study and fabrication of phosphate glass resorbable capillaries [2] that can be used both as local drug delivery system and light guides for the activation of the suitable chemicals. This device allows topical drug administration avoiding side effects and necessity to keep the patient in the dark for several days. Moreover, the specific formulation of the glass permits full bioresorbability within 20 days thus not requiring explant surgery. Release kinetics of several photosensitive and test drugs are also reported, e.g. Rose Bengal.

References

[1] A. R. Azzouzi et al., “Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial,” Lancet Oncol. In press, doi: 10.1016/S1470-2045(16)30661-1 (2016).

[2] E. Ceci-Ginistrelli et al., “Drug release kinetics from biodegradable UV-transparent hollow calcium-phosphate glass fibers,” Mater. Lett. In press, doi: 10.1016/j.matlet.2016.12.103.